ImmunoCellular Therapeutics
Calabasas
About ImmunoCellular Therapeutics
ImmunoCellular Therapeuti is a clinical-stage biotechnology company. It is engaged in developing immune-based therapies for the treatment of cancers which can elicit an immune response against several antigens. The company has developed ICT-107, which is a dendritic cell (DC) immunotherapy for the treatment of newly diagnosed glioblastoma multiforme (GBM), which is a lethal type of brain cancer. It develops Immunotherapies for treating cancer in which a patient's own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $32.5M
- Funding stage: IPO
- Last round: Grant (Sep 2015)
- Ticker: nysemkt:IMUC
- Website: imuc.com
- Phone: (818) 264-2300
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical Device, Oncology
Social Profiles
Canonical: https://fsome.com/organization/immunocellular-therapeutics-1638112 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.